Cargando…

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives

Aberrant c-MET (Mesenchymal–Epithelial Transition) signaling contributes to cancer cell development, proliferation, and metastases of non-small cell lung cancer (NSCLC). MET exon 14 (METex14) skipping mutation is noted in approximately 4% of NSCLC cases and is targetable with the recently approved t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fraser, Madison, Seetharamu, Nagashree, Diamond, Matthew, Lee, Chung-Shien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629434/ https://www.ncbi.nlm.nih.gov/pubmed/37941971 http://dx.doi.org/10.2147/CMAR.S386799

Ejemplares similares

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
por: Lee, Chung-Shien, et al.
Publicado: (2021)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer
por: Wang, Kevin Y, et al.
Publicado: (2021)

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
por: Lee, Chung-Shien, et al.
Publicado: (2020)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu, Nagashree, et al.
Publicado: (2017)

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo, Matthew Z, et al.
Publicado: (2021)

Disparities in lung cancer screening rates among the Hispanic/LatinX population
por: Olazagasti, Coral, et al.
Publicado: (2021)

Disparities in Lung Cancer Screening in Puerto Rico: A United States Colony with Unequal Benefits
por: Olazagasti, Coral, et al.
Publicado: (2021)

One size does not fit all: Evaluating disparities in lung cancer screening eligibility amongst the Hispanic population
por: Olazagasti, Coral, et al.
Publicado: (2022)

Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies
por: Olazagasti, Coral, et al.
Publicado: (2020)

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan, Aaron C, et al.
Publicado: (2021)

Lung cancer screening guidelines are clear but are they being followed?
por: Olazagasti, Coral, et al.
Publicado: (2020)

An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab
por: Lee, Matthew, et al.
Publicado: (2019)

Implementing physician education to increase lung cancer screening uptake
por: Olazagasti, Coral, et al.
Publicado: (2023)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
por: Cravero, Paola, et al.
Publicado: (2020)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Missed Opportunities? An Observational Analysis of Lung Cancer Screening Utilization Amongst Patients With Lung Cancer
por: Olazagasti, Coral, et al.
Publicado: (2022)

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping
por: Yang, Mo, et al.
Publicado: (2023)

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer
por: McCoach, Caroline E., et al.
Publicado: (2021)

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report
por: Choi, Wonyoung, et al.
Publicado: (2022)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
por: Hsu, Robert, et al.
Publicado: (2023)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
por: Chou, Yun-Tse, et al.
Publicado: (2022)

Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer
por: Sandoval, Leticia, et al.
Publicado: (2023)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer
por: Newman, James, et al.
Publicado: (2020)

Impact of Family and Social Network on Tobacco Cessation Amongst Cancer Patients
por: Neumann, Melissa, et al.
Publicado: (2021)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
por: Lavacchi, Daniele, et al.
Publicado: (2019)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

SAT-LB102 When the Answer Is Not in the First Look: An Unusual Presentation of Follicular Thyroid Carcinoma
por: Bernabe Ramirez, Carolina, et al.
Publicado: (2019)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
por: Lefler, Daniel S, et al.
Publicado: (2022)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
por: Wilgucki, Molly, et al.
Publicado: (2022)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
por: Schuler, M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rj4bcghsukv2vigb42abrgk91m